The Genomics core will provide consultation, DNA sequencing, and transcriptional profiling for analysis of both bacterial and mammalian whole genomes to the UW CF research community. The core will also provide data management and analysis tools and create access platforms to integrate data from the clinical and immunology cores, for human samples and bacterial isolates. The advent of ultra-high throughput nucleic acid sequencing technology allows a much greater ability to link disease-causing characteristics of pathogens to their genome-encoded (and expressed) origins. In addition, genetic variation of the human host has become more readily deduced with contemporary technology, even to the extent of sequencing all protein-coding regions of the genome [1, 2], and to measure relative transcript levels of all expressed genes using Illumina RNA-seq technology. The purpose of the Genomics Core is to promote access to technology necessary to use these approaches, and to analyze the data they generate.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK089507-10
Application #
9989217
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Eggerman, Thomas L
Project Start
Project End
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
10
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Quon, Bradley S; Sykes, Jenna; Stanojevic, Sanja et al. (2018) Clinical characteristics of cystic fibrosis patients prior to lung transplantation: An international comparison between Canada and the United States. Clin Transplant 32:e13188
West, Natalie E; Goss, Christopher H; Nichols, David P (2018) The Long and the Short of It in Cystic Fibrosis Clinical Research Outcomes. Ann Am Thorac Soc 15:430-431
Kopp, B T; Joseloff, E; Goetz, D et al. (2018) Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis. J Cyst Fibros :
Bricio-Moreno, Laura; Sheridan, Victoria H; Goodhead, Ian et al. (2018) Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa. Nat Commun 9:2635
Crull, Matthew R; Somayaji, Ranjani; Ramos, Kathleen J et al. (2018) Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study. Clin Infect Dis 67:1089-1095
Heltshe, Sonya L; Rowe, Steven M; Skalland, Michelle et al. (2018) Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement. Am J Respir Crit Care Med 197:1483-1486
Kang, Inkyung; Chang, Mary Y; Wight, Thomas N et al. (2018) Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection. J Histochem Cytochem 66:241-259
Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros :
Goss, Christopher H; Sykes, Jenna; Stanojevic, Sanja et al. (2018) Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. Am J Respir Crit Care Med 197:768-775
Ramos, Kathleen J; Somayaji, Ranjani; Nichols, David P et al. (2018) Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls. Paediatr Drugs 20:1-7

Showing the most recent 10 out of 222 publications